Health tech investor Glen Tullman launches 62 Ventures, a new $100 million fund

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

First the news: Glen Tullman, currently the CEO Transcarent, has a new, roughly $100 million venture fund, called 62 Ventures. The plan, he told me, is to use the new fund to invest in startups that fall outside the strict digital health focus of his well-known fund 7wireVentures. Among his interests will be startups from India, which Tullman called his “home away from home as a country” and where he sees great opportunity. 62 Ventures will also invest U.S.-based companies and aims to write checks between $1 million and $10 million. The fund has already invested in BridgeHealthAI, a startup aimed at “simplifying health and social benefits navigation” for people experiencing health disparities; Khyaal, a “super app” for seniors in India; and Loop Health, a health insurance and integrated care company in India.

On new AI features for Transcarent

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In